Roche has been hit with another exec departure after it said Roland Diggelmann will leave his role as CEO of its diagnostics division to “pursue his career outside of the company”.
China's national regulator has granted a rapid approval for Roche’s lung cancer treatment Alecensa just months after European and American approvals, following a revamp of the country's not
NICE has continued to reject Roche’s Perjeta (pertuzumab) in its use to prevent early-stage HER2-positive breast cancer from recurring after surgery, after reconsidering evidence in the lig
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.